Cross-source evidence timeline
Lutetium Lu 177 dotatate research timeline
Follow 41 selected, directly cited source records from January 26, 2018 through November 16, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Clinical trials
ClinicalTrials.gov record NCT05278208↗
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04234568↗
PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04665739↗
PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04750954↗
PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05178693↗
PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05691465↗
PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05773274↗
PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT06955169↗
PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Literature metadata
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case.↗
PubMed lists PMID 37184824 in European journal of drug metabolism and pharmacokinetics as Journal Article, with publication-date metadata of 2023-05-15 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 15, 2023 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor.↗
PubMed lists PMID 37883194 in Clinical nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2023-10-23 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 23, 2023 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT07910760↗
PeptideScanner retained ClinicalTrials.gov record NCT07910760 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Literature metadata
Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.↗
PubMed lists PMID 38451361 in Journal of neuro-oncology as Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 7, 2024 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05247905↗
PeptideScanner retained ClinicalTrials.gov record NCT05247905 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04082520↗
PeptideScanner retained ClinicalTrials.gov record NCT04082520 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Literature metadata
Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA.↗
PubMed lists PMID 38849643 in Endocrine as Letter, with publication-date metadata of 2024-06-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 7, 2024 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03971461↗
PeptideScanner retained ClinicalTrials.gov record NCT03971461 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05583708↗
PeptideScanner retained ClinicalTrials.gov record NCT05583708 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Regulatory
Drugs@FDA application ANDA217060↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217060 with status AP dated 2026-09-21, and names lutetium lu-177 dotatate among the application record's active ingredients.↗
Added to PeptideScanner November 16, 2026Literature metadata
FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto.↗
PubMed lists PMID 41935511 in Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 1, 2026 · day precisionAdded to PeptideScanner November 16, 2026Regulatory
Drugs@FDA application NDA218525↗
The official Drugs@FDA dataset lists original submission 1 for NDA 218525 with status AP dated 2026-09-14, and names lutetium lu-177 dotatate among the application record's active ingredients.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03457948↗
PeptideScanner retained ClinicalTrials.gov record NCT03457948 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05142696↗
PeptideScanner retained ClinicalTrials.gov record NCT05142696 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05724108↗
PeptideScanner retained ClinicalTrials.gov record NCT05724108 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT06016855↗
PeptideScanner retained ClinicalTrials.gov record NCT06016855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT06326190↗
PeptideScanner retained ClinicalTrials.gov record NCT06326190 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04529044↗
PeptideScanner retained ClinicalTrials.gov record NCT04529044 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04954820↗
PeptideScanner retained ClinicalTrials.gov record NCT04954820 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04261855↗
PeptideScanner retained ClinicalTrials.gov record NCT04261855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04711135↗
PeptideScanner retained ClinicalTrials.gov record NCT04711135 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Literature metadata
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).↗
PubMed lists PMID 36550428 in BMC cancer as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2022-12-22 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 22, 2022 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03972488↗
PeptideScanner retained ClinicalTrials.gov record NCT03972488 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT06395402↗
PeptideScanner retained ClinicalTrials.gov record NCT06395402 at 2026-11-16T01:36:36.861Z. Its registry update date was 2025-07-22, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026
Source year
2023
Literature metadata
Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®.↗
PubMed lists PMID 37930495 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2023-11-06 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 6, 2023 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE.↗
PubMed lists PMID 37111596 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2023-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 31, 2023 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2022
Regulatory
Federal Register notice 2022-25549↗
The Federal Register published notice 2022-25549, attributed to FDA and its parent HHS department, on 2022-11-23. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Lutetium Lu 177 dotatate.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03590119↗
PeptideScanner retained ClinicalTrials.gov record NCT03590119 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-11-08, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026Literature metadata
Lutetium Lu-177 Dotatate Flare Reaction.↗
PubMed lists PMID 33490736 in Advances in radiation oncology as Journal Article, with publication-date metadata of 2020-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 26, 2020 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT01578239↗
PeptideScanner retained ClinicalTrials.gov record NCT01578239 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026
Source year
2021
Literature metadata
Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung.↗
PubMed lists PMID 32616557 in Journal for immunotherapy of cancer as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-07 (month precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 2020 · month precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03325816↗
PeptideScanner retained ClinicalTrials.gov record NCT03325816 at 2026-11-16T01:36:36.861Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗
Added to PeptideScanner November 16, 2026
Source year
2018
Regulatory
Drugs@FDA application NDA208700↗
The official Drugs@FDA dataset lists original submission 1 for NDA 208700 with status AP dated 2018-01-26, and names lutetium lu-177 dotatate among the application record's active ingredients.↗
Added to PeptideScanner November 16, 2026